단순 헤르페스 바이러스 치료 시장 - 바이러스 유형별, 약물 유형별, 투여 부위별, 투여 경로별, 유통 채널별 세계 예측(2023-2032년)

The global Herpes Simplex Virus (HSV) treatment market is expected to register a 4% growth rate during 2023-2032, propelled by advancements in therapeutic approaches, rising awareness about herpes infections, and a growing prevalence of Herpes Simplex Virus-2 (HSV-2).

As per a WHO report in 2023, about 67% of the global population aged below 50 years (3.7 billion) have herpes simplex virus type 1 (HSV-1), causing oral herpes. An estimated 13% of people aged 15-49 years (491 million) has herpes simplex virus type 2 (HSV-2), leading to genital herpes. Many HSV infections are asymptomatic or go unrecognized. As public awareness builds overtime, individuals are becoming more informed about the nature, transmission, and potential complications associated with herpes viruses. The focus on early diagnosis and appropriate treatments is contributing to the demand for advanced therapeutic solutions.

The global Herpes Simplex Virus (HSV) treatment industry is classified based on virus type, drug type, site, route of administration, distribution channel, and region.

The HSV-2 virus type segment is expected to witness sustained growth during the study period driven by its rising prevalence amongst the global population. There is a surge in R&D activities focused on addressing the specific challenges posed by HSV-2, emphasizing the need for specialized treatment options catering to the unique characteristics of this herpes strain.

The valacyclovir drug type segment is set for steady growth through 2032 owing to its efficacy in managing herpes infections by inhibiting viral replication. As a prodrug of acyclovir, valacyclovir enhances bioavailability and ensures prolonged antiviral activity, thereby curbing the infection. Moreover, the drug is effective against both HSV-1 and HSV-2, making it a preferred choice for clinicians and patients alike.

Asia Pacific Herpes Simplex Virus (HSV) treatment market size is anticipated to witness rapid expansion over 2023-2032, driven by a surge in the prevalence of herpes infections, necessitating increased attention to treatment and management strategies. Countries like China and India are experiencing notable advancements in healthcare infrastructure. Also, there is a growing awareness of sexually transmitted infections, contributing to the demand for effective herpes treatment solutions. The favourable healthcare policies in the region will shape the industry dynamics in the coming years.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Forecast calculation
• 1.4 COVID-19 impact analysis at global level
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Herpes simplex virus treatment industry 360 degree synopsis, 2018 - 2032 (USD Million)
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Virus type trends
  • 2.1.4 Drug type trends
  • 2.1.5 Site trends
  • 2.1.6 Route of administration trends
  • 2.1.7 Distribution channel trends

Chapter 3 Herpes Simplex Virus Treatment Market Insights

• 3.1 Industry landscape, 2018 - 2032 (USD Million)
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of herpes infection
    • 3.2.1.2 Rising research and development
    • 3.2.1.3 Increasing government funding and awareness
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Increasing product recalls
    • 3.2.2.2 Unavailability of vaccines
• 3.3 Growth potential analysis
  • 3.3.1 By virus type
  • 3.3.2 By drug type
  • 3.3.3 By site
  • 3.3.4 By route of administration
  • 3.3.5 By distribution channel
• 3.4 COVID-19 impact analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis, 2022
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard, 2022

Chapter 5 Herpes Simplex Virus Treatment Market Estimates and Forecast, By Virus Type, 2018-2032 (USD Million)

• 5.1 Key trends, by virus type
• 5.2 Herpes simplex virus 1
• 5.3 Herpes simplex virus 2

Chapter 6 Herpes Simplex Virus Treatment Market Estimates and Forecast, By Drug Type, 2018-2032 (USD Million)

• 6.1 Key trends, by drug type
• 6.2 Acyclovir
• 6.3 Valacyclovir
• 6.4 Famciclovir
• 6.5 Other drug types

Chapter 7 Herpes Simplex Virus Treatment Market Estimates and Forecast, By Site, 2018-2032 (USD Million)

• 7.1 Key trends, by site
• 7.2 Oral
• 7.3 Genital
• 7.4 Other sites

Chapter 8 Herpes Simplex Virus Treatment Market Estimates and Forecast, By Route of Administration, 2018-2032 (USD Million)

• 8.1 Key trends, by route of administration
• 8.2 Oral
• 8.3 Injectable
• 8.4 Topical

Chapter 9 Herpes Simplex Virus Treatment Market Estimates and Forecast, By Distribution Channel, 2018-2032 (USD Million)

• 9.1 Key trends, by distribution channel
• 9.2 Hospital pharmacy
• 9.3 Retail pharmacy
• 9.4 Online pharmacy

Chapter 10 Herpes Simplex Virus Treatment Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)

• 10.1 Key trends, by region
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East & Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 Rest of Middle East & Africa

Chapter 11 Company Profiles

• 11.1 GlaxoSmithKline plc
• 11.2 Pfizer Inc
• 11.3 Teva Pharmaceutical Industries Ltd
• 11.4 Glenmark Pharmaceuticals Limited
• 11.5 Amneal Pharmaceuticals LLC
• 11.6 Novartis AG
• 11.7 Abbott Laboratories
• 11.8 Fresenius Kabi AG
• 11.9 Emcure Pharmaceuticals Ltd
• 11.10 Viatris Inc.